Showing posts with label Strategy. Show all posts
Showing posts with label Strategy. Show all posts

Sunday, 17 June 2012

Dow Jones Industrial Average-Strategy Consulting-Difficult Period-Bear Market

Bear Market Advice and Perspectives

Our management and strategy consulting firm was founded in November 2008, which was clearly a difficult period for the U.S. economy and a year that many investors would like to forget. The Dow Jones Industrial average recorded its worst annual performance since 1931 and the NASDAQ Composite had its worst year since inception in 1971.  [...] read more..

Tuesday, 20 March 2012

The European Association Of Urology-Prostate Cancer

The challenge of prostate cancer drug approval versus reimbursement

Here at the European Association of Urology (EAU) congress in Paris, there are some interesting debates amongst delegates attending the meeting regarding new therapies either recently – or about to be approved – for castrate-resistant prostate cancer (CRPC). For example: … Continue reading ? read more..

Monday, 19 March 2012

Cancer News-News Wires-Research

J&J unblind Zytiga phase 3 trial in pre-chemotherapy castrate-resistant prostate cancer

The big cancer news that hit the news wires this morning was not entirely surprising: “Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA (abiraterone acetate) plus prednisone for the treatment of … Continue reading ? read more..